Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma.
Biomarker and diagnostic research for combined small cell lung carcinoma has been reported in the published literature.
No clinical trials have been registered for combined small cell lung carcinoma.
206 publications have been identified in PubMed for combined small cell lung carcinoma. Research spans Review / Meta-Analysis (29%), Basic Science / Preclinical (21%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 59 | 29% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 12:56 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Laboratory research
43 |
21% |
Clinical study results | 36 | 17% |
Disease patterns and progression | 24 | 12% |
Testing and diagnosis research | 21 | 10% |
New treatment approaches | 12 | 6% |
Patient case studies | 11 | 5% |
Yeung AML (2026). [PMID: 41653583](https://pubmed.ncbi.nlm.nih.gov/41653583/). *Clinical lung cancer*. [Review / Meta-Analysis]
Vianello M (2026). [PMID: 41560507](https://pubmed.ncbi.nlm.nih.gov/41560507/). *Ann Palliat Med*. [Review / Meta-Analysis]
Wang N (2026). [PMID: 41608560](https://pubmed.ncbi.nlm.nih.gov/41608560/). *Theranostics*. [Basic Science / Preclinical]
Gao P (2026). [PMID: 41664836](https://pubmed.ncbi.nlm.nih.gov/41664836/). *Future Oncol*. [Diagnostic / Biomarker]
González-Montero J (2026). [PMID: 41946650](https://pubmed.ncbi.nlm.nih.gov/41946650/). *Ther Deliv*. [Review / Meta-Analysis]
Xiao Y (2026). [PMID: 41789426](https://pubmed.ncbi.nlm.nih.gov/41789426/). *Front Cell Infect Microbiol*. [Review / Meta-Analysis]
Solanki HS (2026). [PMID: 41165456](https://pubmed.ncbi.nlm.nih.gov/41165456/). *Cancer Res*. [Gene Therapy / Novel Therapeutics]
Zargham R (2026). [PMID: 41549059](https://pubmed.ncbi.nlm.nih.gov/41549059/). *Diagn Cytopathol*. [Diagnostic / Biomarker]
Ding W (2026). [PMID: 41913550](https://pubmed.ncbi.nlm.nih.gov/41913550/). *Ann Med*. [Clinical Trial Publication]
Wijaya JE (2026). [PMID: 42199819](https://pubmed.ncbi.nlm.nih.gov/42199819/). *SAGE Open Med Case Rep*. [Case Report / Case Series]
AI-curated news mentioning combined small cell lung carcinoma
Updated Mar 27, 2026
EMA recommends marketing authorization for Imdylltra (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer. This treatment addresses a significant unmet need in a challenging cancer subtype.
Excalipoint Therapeutics has secured $68.7 million in seed funding to develop next-generation T cell engagers targeting small cell lung cancer and neuroendocrine tumors. Backed by Lilly, the startup aims to advance its innovative cancer therapy pipeline.